Shopping Cart 0
Cart Subtotal
USD 0

University of California San Francisco - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

University of California San Francisco (UCSF), a subsidiary of University of California is an educational university that offers biomedical research and graduate-level educational programs in various fields. The university provides resourcing and training programs; education, research and patient care services. It provides professional educational courses in dentistry, medicine, nursing and pharmacy. UCSF serves in the areas of cancer, children's health, diabetes, heart and vascular; immunology and infectious diseases; stem cells, transplant services, neurology and neurosurgery; translational medicine and women's health. The university conducts research in the areas of basic science investigation, translational research and precision medicine. It collaborates with hospitals, medical centers, trauma centers, research institutes and research centers. UCSF is headquartered in San Francisco, California, the US.

University of California San Francisco-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Francisco, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University of California San Francisco, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Protagen Enters into Agreement with University of California, San Francisco 15

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 16

Apexigen Enters into Agreement with University of California San Francisco 17

Strata Oncology Enters into Agreement with University of California 18

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 19

Xynomic Pharma Enters into Agreement with University of California San Francisco 20

Xcell Biosciences Enters into Partnership with University of California, San Francisco 21

Selvita Enters into Agreement with University of California, San Francisco 22

Natera Enters into Research Agreement with University of California, San Francisco 23

UCSF Partners with Berkeley Lights 24

BioCision Partners with University of California 25

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 26

Celgene Partners with Recombinant Antibody Network 27

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 28

Sutro Biopharma Enters into Agreement with University of California, San Francisco 29

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 30

Navidea Biopharma Amends Agreement with University of California San Francisco 31

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 32

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 34

Centers For Therapeutic Innovation Partners with UC San Francisco 35

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 36

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 37

University of California Enters Into Research Agreement With Sanofi 38

Licensing Agreements 39

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 39

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 40

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 41

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 42

University of California San Francisco Enters into Licensing Agreement with Mitokinin 43

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 44

SeraCare Life Sciences Enters into Licensing Agreement with University of California 45

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 46

University of California San Francisco-Key Competitors 47

University of California San Francisco-Key Employees 48

University of California San Francisco-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Joint Venture 51

Recent Developments 52

Government and Public Interest 52

Sep 06, 2018: Newfound Inhibitors to CRISPR Could Improve Gene Editing 52

Sep 06, 2018: Innovative Technique Reveals 'Core Identities' of Brain Cells 53

Sep 06, 2018: 'Biosimilar' Drugs for Rheumatoid Arthritis Actually Cost Patients More 54

Sep 05, 2018: NIH funds UCSF-led initiative to chart a course toward new psychiatric drugs 55

Aug 16, 2018: New Approach to Fight Tuberculosis, a Leading Cause of Death Worldwide 57

Jul 19, 2018: CRISPR-Based Tool Maps Gene Function in Human Cells 59

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 62

Jul 18, 2018: RPB and AAO award grants for big data research to advance patient care-Research to prevent blindness 63

Jul 12, 2018: UCSF study finds simplified systems intervention improves blood pressure control in safety-net settings 64

Jul 10, 2018: T Cell Engineering Breakthrough Sidesteps Need for Viruses in CRISPR Gene-Editing 66

Jul 03, 2018: New Form Of Wound Healing Revealed By Parasitic Gut Worms 68

Jul 02, 2018: Study: Zika could cause more miscarriages than we realize 70

Jun 26, 2018: New study links poor sleep quality to atrial fibrillation 71

Jun 25, 2018: Immune Profile for Successful Cancer Immunotherapy Discovered 72

May 17, 2018: Roth, Johnson awarded USD 28 million for Illuminating Druggable Genome NIH grants 74

Apr 17, 2018: National MS Society Commits USD 14.2 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever 75

Apr 17, 2018: Gene Mapping Lays Groundwork for Precision Chemotherapy 76

Apr 03, 2018: American Heart Association awards USD 2 million to fund leading heart researchers 78

Mar 26, 2018: Aggressive Growth of Common Brain Tumors Linked to Single Gene 79

Feb 06, 2018: Immune system dysfunction may occur early in Alzheimer's disease 80

Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 81

Dec 17, 2017: New Information Standard Announced For PDX Models To Improve Cancer Research 84

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 85

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 86

Oct 27, 2017: Study uses genomics to make treatment recommendations for recurrent glioblastoma patients 87

Oct 16, 2017: Gilead Awards USD 7.5 Million in Second Round of Grants to Advance HIV Cure Research 90

Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 91

May 31, 2017: Researchers Explore the Possible Link between CMV Infection, Obesity, and Metabolic Syndrome 93

May 15, 2017: USD 2.6 Million in New Grants Spurs Innovation 94

Product News 97

Dec 21, 2017: Lethal cancer treatment enters clinical trial 97

Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 98

Mar 07, 2018: UC Davis researchers find new way to defeat HIV latency 99

Jan 26, 2018: UCSF-led clinical trial model may present a better way to test new breast cancer drugs 101

Other Significant Developments 102

Aug 02, 2018: Newly published data demonstrate bone in-growth potential of Stryker's 3D-Printed Tritanium Cage 102

Jul 12, 2018: Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer 103

Feb 22, 2018: OncLive Hosts State of the Science Summit: Gastrointestinal Malignancies 104

Appendix 105

Methodology 105

About GlobalData 105

Contact Us 105

Disclaimer 105


List Of Figure

List of Figures

University of California San Francisco, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University of California San Francisco, Pharmaceuticals & Healthcare, Key Facts 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Francisco, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Protagen Enters into Agreement with University of California, San Francisco 15

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 16

Apexigen Enters into Agreement with University of California San Francisco 17

Strata Oncology Enters into Agreement with University of California 18

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 19

Xynomic Pharma Enters into Agreement with University of California San Francisco 20

Xcell Biosciences Enters into Partnership with University of California, San Francisco 21

Selvita Enters into Agreement with University of California, San Francisco 22

Natera Enters into Research Agreement with University of California, San Francisco 23

UCSF Partners with Berkeley Lights 24

BioCision Partners with University of California 25

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 26

Celgene Partners with Recombinant Antibody Network 27

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 28

Sutro Biopharma Enters into Agreement with University of California, San Francisco 29

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 30

Navidea Biopharma Amends Agreement with University of California San Francisco 31

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 32

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 34

Centers For Therapeutic Innovation Partners with UC San Francisco 35

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 36

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 37

University of California Enters Into Research Agreement With Sanofi 38

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 39

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 40

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 41

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 42

University of California San Francisco Enters into Licensing Agreement with Mitokinin 43

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 44

SeraCare Life Sciences Enters into Licensing Agreement with University of California 45

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 46

University of California San Francisco, Key Competitors 47

University of California San Francisco, Key Employees 48

University of California San Francisco, Subsidiaries 49

University of California San Francisco, Joint Venture 51

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

University of California San Francisco, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

University of California San Francisco (UCSF), a subsidiary of University of California is an educational university that offers biomedical research and graduate-level educational programs in various fields. The university provides resourcing and training programs; education, research and patient care services. It provides professional educational courses in dentistry, medicine, nursing and pharmacy. UCSF serves in the areas of cancer, children's health, diabetes, heart and vascular; immunology and infectious diseases; stem cells, transplant services, neurology and neurosurgery; translational medicine and women's health. The university conducts research in the areas of basic science investigation, translational research and precision medicine. It collaborates with hospitals, medical centers, trauma centers, research institutes and research centers. UCSF is headquartered in San Francisco, California, the US.

University of California San Francisco-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Francisco, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University of California San Francisco, Pharmaceuticals & Healthcare, Deal Details 15

Partnerships 15

Protagen Enters into Agreement with University of California, San Francisco 15

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 16

Apexigen Enters into Agreement with University of California San Francisco 17

Strata Oncology Enters into Agreement with University of California 18

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 19

Xynomic Pharma Enters into Agreement with University of California San Francisco 20

Xcell Biosciences Enters into Partnership with University of California, San Francisco 21

Selvita Enters into Agreement with University of California, San Francisco 22

Natera Enters into Research Agreement with University of California, San Francisco 23

UCSF Partners with Berkeley Lights 24

BioCision Partners with University of California 25

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 26

Celgene Partners with Recombinant Antibody Network 27

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 28

Sutro Biopharma Enters into Agreement with University of California, San Francisco 29

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 30

Navidea Biopharma Amends Agreement with University of California San Francisco 31

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 32

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 34

Centers For Therapeutic Innovation Partners with UC San Francisco 35

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 36

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 37

University of California Enters Into Research Agreement With Sanofi 38

Licensing Agreements 39

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 39

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 40

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 41

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 42

University of California San Francisco Enters into Licensing Agreement with Mitokinin 43

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 44

SeraCare Life Sciences Enters into Licensing Agreement with University of California 45

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 46

University of California San Francisco-Key Competitors 47

University of California San Francisco-Key Employees 48

University of California San Francisco-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Joint Venture 51

Recent Developments 52

Government and Public Interest 52

Sep 06, 2018: Newfound Inhibitors to CRISPR Could Improve Gene Editing 52

Sep 06, 2018: Innovative Technique Reveals 'Core Identities' of Brain Cells 53

Sep 06, 2018: 'Biosimilar' Drugs for Rheumatoid Arthritis Actually Cost Patients More 54

Sep 05, 2018: NIH funds UCSF-led initiative to chart a course toward new psychiatric drugs 55

Aug 16, 2018: New Approach to Fight Tuberculosis, a Leading Cause of Death Worldwide 57

Jul 19, 2018: CRISPR-Based Tool Maps Gene Function in Human Cells 59

Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 62

Jul 18, 2018: RPB and AAO award grants for big data research to advance patient care-Research to prevent blindness 63

Jul 12, 2018: UCSF study finds simplified systems intervention improves blood pressure control in safety-net settings 64

Jul 10, 2018: T Cell Engineering Breakthrough Sidesteps Need for Viruses in CRISPR Gene-Editing 66

Jul 03, 2018: New Form Of Wound Healing Revealed By Parasitic Gut Worms 68

Jul 02, 2018: Study: Zika could cause more miscarriages than we realize 70

Jun 26, 2018: New study links poor sleep quality to atrial fibrillation 71

Jun 25, 2018: Immune Profile for Successful Cancer Immunotherapy Discovered 72

May 17, 2018: Roth, Johnson awarded USD 28 million for Illuminating Druggable Genome NIH grants 74

Apr 17, 2018: National MS Society Commits USD 14.2 Million to New Research to Stop Multiple Sclerosis, Restore Function and End MS Forever 75

Apr 17, 2018: Gene Mapping Lays Groundwork for Precision Chemotherapy 76

Apr 03, 2018: American Heart Association awards USD 2 million to fund leading heart researchers 78

Mar 26, 2018: Aggressive Growth of Common Brain Tumors Linked to Single Gene 79

Feb 06, 2018: Immune system dysfunction may occur early in Alzheimer's disease 80

Jan 23, 2018: Damon Runyon Cancer Research Foundation awards USD 3M to eleven innovative early career scientists 81

Dec 17, 2017: New Information Standard Announced For PDX Models To Improve Cancer Research 84

Dec 14, 2017: Research Targeting Diabetes, Liver Failure and HIV Get Support from California Stem Cell Agency 85

Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 86

Oct 27, 2017: Study uses genomics to make treatment recommendations for recurrent glioblastoma patients 87

Oct 16, 2017: Gilead Awards USD 7.5 Million in Second Round of Grants to Advance HIV Cure Research 90

Oct 06, 2017: FDA awards 15 grants for clinical trials to stimulate product development for rare diseases 91

May 31, 2017: Researchers Explore the Possible Link between CMV Infection, Obesity, and Metabolic Syndrome 93

May 15, 2017: USD 2.6 Million in New Grants Spurs Innovation 94

Product News 97

Dec 21, 2017: Lethal cancer treatment enters clinical trial 97

Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 98

Mar 07, 2018: UC Davis researchers find new way to defeat HIV latency 99

Jan 26, 2018: UCSF-led clinical trial model may present a better way to test new breast cancer drugs 101

Other Significant Developments 102

Aug 02, 2018: Newly published data demonstrate bone in-growth potential of Stryker's 3D-Printed Tritanium Cage 102

Jul 12, 2018: Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer 103

Feb 22, 2018: OncLive Hosts State of the Science Summit: Gastrointestinal Malignancies 104

Appendix 105

Methodology 105

About GlobalData 105

Contact Us 105

Disclaimer 105


List Of Figure

List of Figures

University of California San Francisco, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University of California San Francisco, Pharmaceuticals & Healthcare, Key Facts 2

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University of California San Francisco, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University of California San Francisco, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University of California San Francisco, Deals By Therapy Area, 2012 to YTD 2018 10

University of California San Francisco, Medical Devices Deals, 2012 to YTD 2018 11

University of California San Francisco, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Protagen Enters into Agreement with University of California, San Francisco 15

Tyme Technologies Enters into Co-development Agreement with University of California San Francisco 16

Apexigen Enters into Agreement with University of California San Francisco 17

Strata Oncology Enters into Agreement with University of California 18

ShangPharma Innovation Enters into Partnership with the University of California San Francisco 19

Xynomic Pharma Enters into Agreement with University of California San Francisco 20

Xcell Biosciences Enters into Partnership with University of California, San Francisco 21

Selvita Enters into Agreement with University of California, San Francisco 22

Natera Enters into Research Agreement with University of California, San Francisco 23

UCSF Partners with Berkeley Lights 24

BioCision Partners with University of California 25

UC San Francisco Enters into Research Agreement with GlaxoSmithKline 26

Celgene Partners with Recombinant Antibody Network 27

BioMotiv, University of California San Francisco and University of Washington Center for Commercialization Form Joint Venture 28

Sutro Biopharma Enters into Agreement with University of California, San Francisco 29

Daiichi Sankyo Enters Into Co-Development Agreement With UCSF 30

Navidea Biopharma Amends Agreement with University of California San Francisco 31

NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 32

Onyx Pharma And UCSF Helen Diller Family Comprehensive Cancer Center Enter Into Co-Development Agreement 34

Centers For Therapeutic Innovation Partners with UC San Francisco 35

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 36

DNAnexus Enters Into Co-Development Agreement With Geisinger Health System And University of California 37

University of California Enters Into Research Agreement With Sanofi 38

Vanda Pharma Enters into Licensing Agreement with UC San Francisco 39

Fortis Therapeutics Enters into Licensing Agreement with University of California, San Francisco 40

Optikira Enters into Licensing Agreement with University of California, San Francisco and University of Washington 41

Calico Life Sciences Enters into Licensing Agreement with University of California, San Francisco 42

University of California San Francisco Enters into Licensing Agreement with Mitokinin 43

Pliant Therapeutics Enters into Licensing Agreement with UC San Francisco 44

SeraCare Life Sciences Enters into Licensing Agreement with University of California 45

NeoStem Enters Into Licensing Agreement With University of California, San Francisco 46

University of California San Francisco, Key Competitors 47

University of California San Francisco, Key Employees 48

University of California San Francisco, Subsidiaries 49

University of California San Francisco, Joint Venture 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

University of California San Francisco, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.